Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published February 13, 2014 | Accepted Version
Journal Article Open

Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy

Abstract

Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent HIV-1 infection in humanized mice and macaques when passively transferred. New single-cell-based methods have uncovered many broad and potent donor-derived antibodies, and structural studies have revealed the molecular bases for their activities. The new data suggest why such antibodies are difficult to elicit and inform HIV-1 vaccine development efforts. In addition to protecting against infection, the newly identified antibodies can suppress active infections in mice and macaques, suggesting they could be valuable additions to anti-HIV-1 therapies and to strategies to eradicate HIV-1 infection.

Additional Information

© 2014 Elsevier Inc. Available online 13 February 2014. We thank Susan Zolla-Pazner for helpful discussions and critical review. This work was supported by a Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill and Melinda Gates Foundation (Grant ID: 1040753 to P.J.B. and M.C.N.), National Institutes of Health grant HIVRAD P01 AI100148 (P.J.B. and M.C.N.) and award number DP1OD006961 (to P.J.B.), NIH Center for HIV/AID Vaccine Immunology and Immunogen Discovery (CHAVI-ID) 1UM1 AI100663-01 (M.C.N.), and the American Cancer Society (Grant PF-13-076-01-MPC to L.S.). F.K. was supported by the Stavros Niarchos Foundation.

Attached Files

Accepted Version - nihms-568245.pdf

Files

nihms-568245.pdf
Files (1.2 MB)
Name Size Download all
md5:17fb779d8567802cfe66649aa4b5b8bc
1.2 MB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 25, 2023